(Total Views: 464)
Posted On: 09/04/2021 8:33:26 AM
Post# of 36564
I've never understood the posts here and on other boards questioning the validity of past research. Generex has a ton of well respected scientists on board. They wouldn't be with us if they did not feel the science had a chance.
Generex's ability to get adequate financing in order to move forward from past failures and positive results is the problem. The Veneto deal was supposed to fix that. Excellagen sales sales were supposed to fix that. The IPO of NGIO was supposed to fix that. Having a Covid vaccine approved by the FDA would certaily fix things.
Generex, what is holding up the IND? What is the reason for the delay in the SEC approving the S-1 for NGIO? Why are you not being forthcoming with shareholders about the reasons for the delays?
RJS, any idea what the status of Dr Eagle being approved as the COB of NGIO is?
Generex's ability to get adequate financing in order to move forward from past failures and positive results is the problem. The Veneto deal was supposed to fix that. Excellagen sales sales were supposed to fix that. The IPO of NGIO was supposed to fix that. Having a Covid vaccine approved by the FDA would certaily fix things.
Generex, what is holding up the IND? What is the reason for the delay in the SEC approving the S-1 for NGIO? Why are you not being forthcoming with shareholders about the reasons for the delays?
RJS, any idea what the status of Dr Eagle being approved as the COB of NGIO is?
(8)
(0)
